Study Of SU011248 In Combination With Docetaxel In Patients With Advanced Cancer
Status:
Completed
Trial end date:
2007-11-01
Target enrollment:
Participant gender:
Summary
This study is determining the maximum tolerated dose and safety of SU011248 (sunitinib
malate, SUTENT) in combination with docetaxel (Taxotere). Several dosing regimens will be
tested in patients with advanced solid tumors, including non small cell lung cancer.